Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 105, Issue 6, 2010, Pages 770-778

  Da Silva, Adriana Cristina ^a,b   Spina, Ângela Maria Miranda ^b   Lemos, Marcílio Figueiredo ^b   Oba, Isabel Takano ^b   De Fátima Guastini, Cristina ^a   Gomes Gouvêa, Michele Soares ^a   Pinho, João Renato Rebello ^a,c   Mendes Correa, Maria Cássia Jacintho ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Genotype G; Genotypes; Hepatitis B; HIV; Lamivudine; Mutation

Indexed keywords

CERCOPITHECINE HERPESVIRUS 1; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77958021521     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/s0074-02762010000600007     Document Type: Article

References (44)

1. Benhamou Y 2007. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 45 (Suppl. 2): S57-65.
2. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T 1999. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30: 1302-1306.
3. Bonacini M, Louie S, Bzowej N, Wohl Ar 2004. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18: 2039-2045.
4. Bottecchia M, Souto FJ, O KM, Amendola M, Brandão CE, Niel C, Gomes SA 2008. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol 22: 8-11.
5. Braga WS, Brasil LM, de Souza rA, Castilho M da C, da Fonseca JC 2001. The occurrence of hepatitis B and delta virus infection within seven Amerindian ethnic groups in the Brazilian western Amazon. Rev Soc Bras Med Trop 34: 349-355.
6. Braga WS, Silva EB, Souza Tosta CE 2005. Seroprevalence of hepatitis B and malaria infection in Lábrea, Brazilian western Amazon: estimates of coinfection rates. Rev Soc Bras Med Trop 38: 218-223.
7. Chomczynski P, Sacchi N 1987. Single-step method of rNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
8. Da Silva LC, Pinho Jr, Sitnik R, Da Fonseca LE, Carrilho FJ 2001. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 36: 476-485.
9. Ewing B, Green P 1998. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 8: 186-194.
10. Ewing B, Hillier L, Wendl MC, Green P 1998. Base-calling of automated sequencer traces using phred I. Accuracy assessment. Genome Res 8: 175-185.
11. Focaccia da Conceição OJ, Sette H Jr, Sabino E, Bassit L, Nitrini Dr, Lomar AV, Lorenço Vieira De Souza F, Kiffer Cr, Santos EB, Gonzales MP, Sáez-Alquézar A, riscal Jr, Fischer D 1998. Estimated prevalence of viral hepatitis in the general population of the municipality of São Paulo, measured by a serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 2: 269-284.
12. Hall TA 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
13. Huang X, Madan A 1999. CAP3: a DNA sequence assembly program. Genome Res 9: 868-877.
14. Kato H, Orito E, Gish rG, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M 2002. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). J Virol 76: 6131-6137.
15. Kirkwood BR2003. Univariate analysis and chi-square test. In BRKirkwood, JAC Sterne, Essential medical statistics, Blackwell Science, Malden, 501 pp.
16. Lada O, Gervais A, Branger M, Peytavin G, Collin G, Fraqueiro G, Moucari R, Males S, Martinot-Peignoux M, Matheron S, Marcellin P 2008. De novo combination therapy of tenofovir disoproxil fumarate (TDF) plus lamivudine (LAM) or TDF plus emtricitabine (FTC) is associated with early virologic response in HIV/HBV co-infected patients. Hepatology 48: 720A.
17. Lobato C, Tavares-Neto J, rios-Leite M, Trepo C, Vitvitski L, Parvaz P, Zoulim F, D'Oliveira A Jr, Paraná r 2006. Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: epidemiologic and biomolecular study. J Gastroenterol Hepatol 21: 863-868.
18. Lok AS, McMahon BJ 2009. Chronic hepatitis B: update 2009. Hepatology 50: 661-662.
19. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man rA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, rousseau F 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455.
20. Matthews GV, Avihingsanon A, Lewin Sr, Amin J, rerknimitr Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, ruxrungtham K, Dore GJ 2008. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 48: 1062-1069.
21. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL 2006. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20: 863-870.
22. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin Sr, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL 2009. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 23: 1707-1715.
23. Mendes-Correa MC, Barone AA, Cavalheiro N, Tengan FM, Guastini C 2000. Prevalence of hepatitis B and C in the sera of patients with HIV infection in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo 42: 81-85.
24. Mendes-Correa MC, Pinho Jr, Leite OM, Martins LG, Leite AG, Silva MH, Sitnik R, Uip DE 2008. Hepatitis B genotype distribution and high frequency of lamivudine resistance mutations in Brazilian HIV/hepatitis B virus co-infected patients. Hepatology 48: 538A.
25. Monteiro Mr, do Nascimento MM, Passos AD, Figueiredo JF 2004. Soroepidemiological survey of hepatitis B virus among HIV/AIDS patients in Belém, Pará-Brasil. Rev Soc Bras Med Trop 37 (Suppl. 2): 27-32.
26. Pereira LM, Martelli CM, Merchán-Hamann E, Montarroyos UR, Braga MC, de Lima ML, Cardoso Mr, Turchi MD, Costa MA, de Alencar LC, Moreira rC, Figueiredo GM, Ximenes rA 2009. Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg 81: 240-247.
27. Pinho Jr, Santos CA, Gonzalez CL, Bassit L, Barreto CC, Saez-Alquezar A, França AV, Carrilho FJ, Fonseca LE, Chamone DA, da Silva LC 1993. Detection of hepatitis B virus DNA by the polymerase chain reaction in anti-HBe positive chronic hepatitis B patients. Rev Inst Med Trop Sao Paulo 35: 515-520.
28. Portelinha Filho AM, do Nascimento CU, Tannouri TN, Troiani C, Ascêncio EL, Bonfim R, D'Andrea LAZ, Prestes-Carneiro LE 2009. Seroprevalence of HBV, HCV and HIV co-infection in selected individuals from state of São Paulo, Brazil. Mem Inst Oswaldo Cruz 104: 960-963.
29. Sánchez LV, Tanaka Y, Maldonado M, Mizokami M, Panduro A 2007. Difference of hepatitis B virus genotype distribution in two groups of Mexican patients with different risk factors. High prevalence of genotype H and G. Intervirology 50: 9-15.
30. Santos EA, Sucupira MV, Arabe J, Gomes SA 2004. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis 4: 29.
31. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28: 112-125.
32. Sitnik Pinho Jr, Bertolini DA, Bernardini AP, Da Silva LC, Carrilho FJ 2004. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. J Clin Microbiol 42: 2455-2460.
33. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, rockstroh J 2008. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22: 1399-1410.
34. Soriano V, Tuma P, Vispo E, Labarga P, Fernández JV, Medrano J, Barreiro P 2009. Hepatitis B in HIV patients: what is the current treatment and what are the challenges? J HIV Ther 14: 13-18.
35. Souza MG, Passos AD, Machado AA, Figueiredo JF, Esmeraldino LE 2004. HIV and hepatitis B virus co-infection: prevalence and risk factors. Rev Soc Bras Med Trop 37: 391-395.
36. Sucupira MVF, Mello FCA, Santos EA, Niel C, rolla VC, Arabe J, Gomes SA 2006. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 101: 655-660.
37. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, Yoshizawa H, Mishiro S 1995. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 76: 3159-3164.
38. Tamura K, Dudley J, Nei M, Kumar S 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
39. Tavares-Neto J, Almeida D, Soares MC, Uchoa R, Viana S, Darub Farias E, rocha G, Vitvitski L, Paraná r 2004. Seroprevalence of hepatitis B and C in the Western Brazilian Amazon region (rio Branco, Acre): a pilot study carried out during a hepatitis B vaccination program. Braz J Infect Dis 8: 133-139.
40. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG 1997. The CLUSTAL_X Windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
41. Torresi J 2002. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25: 97-106.
42. Tovo CV, Dos Santos DE, de Mattos AZ, de Almeida Pr, de Mattos AA, Santos Br 2006. Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital. Arq Gastroenterol 43: 73-76.
43. Tuma P, Bottecchia M, Sheldon J, Medrano J, Vispo E, Madejón A, Martin-Carbonero L, Barreiro P, Soriano V 2008. Prior lamivudine (LAM) failure may delay time to complete HBV-DNA suppression in HIV patients treated with tenofovir plus LAM. Hepatology 48: 740A.
44. Zago AM, Machado TF, Cazarim FL, Miranda AE 2007. Prevalence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitória, Brazil. Braz J Infect Dis 11: 475-478.